World Clinical Biomarkers and Companion Diagnostics Summit on October 05-08, 2026 in Boston, United States

As regulatory headwinds turn to tailwinds, precision medicine is shifting into a new gear.

Evolving FDA approaches to LDTs and 510(k) pathways are removing long-standing friction, coordinated Rx-Dx launches are gaining pace, ctDNA and MRD are advancing as clinically meaningful endpoints, and reimbursement expansion is improving access to high-value genomic testing. At the same time, innovation in multiplex assays, multi-omics platforms, liquid biopsy, digital pathology, spatial biology, and AI-powered diagnostics, are rapidly reshaping the IVD landscape.

Fueled by $60B+ in diagnostic deal-making and strategic partnerships, the 16th World Clinical Biomarkers and Companion Diagnostics Summit returns as the industry's esteemed end-to-end precision medicine forum. Convening 850+ senior leaders from biopharma, diagnostic, regulatory, healthcare, testing labs and multimodal communities, this meeting will span the full value chain; from biomarker discovery to clinical validation, approval and real-world adoption, across a diverse range of technologies and disease areas.

Now expanded into five focused content tracks, join us in harnessing the speed, scale, and growing complexity of innovation happening in next-generation IVD platforms, multimodal data, and CDx development.

URLs:

Tickets: https://go.evvnt.com/3656069-2?pid=10008

Brochure: https://go.evvnt.com/3656069-3?pid=10008

Time: 8:30 AM - 2:50 PM

Prices:

Drug Developer and Academic Pricing (Conference + Engagers/Workshops): USD 0.50,

Drug Developer and Academic Pricing (Conference Only): USD 0.50,

Solution and Service Provider Pricing (Conference Only): USD 3999.00

Speakers: Amy Gorman, International Precision Medicine and Diagnostics Commercial Leader, AbbVie, Danielle Townsley, Executive Director and Precision Medicine Therapeutic Area Head, Oncology, Amgen, Diarmuid Moran, Head of Precision Medicine and Diagnostics (R and D), Astellas Pharma, Mark Gustavson, Senior Director, Computational Pathology, AstraZeneca, Etai Jacob, Head, Applied Data Science and AI, Oncology R and D, AstraZeneca, John W. Longshore, Head, Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, Adriana Racolta, Senior Director, Global Regulatory Leader, IVD, Bayer, Jon Baden, Executive Director and Head, Precision Medicine, Bristol Myers Squibb, Jilian Golding, Global Commercial Strategy, Precision Medicine Lead, Bristol Myers Squibb, Christina Bender, Director, Global Oncology Marketing, Biomarker Strategy, Daiichi Sankyo, Peter Krein, Vice President, Diagnostic Development, Eli Lilly and Co, Amy H. Kao, Senior Vice President, Global Head, Research Unit, and Neuroscience, Immunology and Billerica Campus Head, EMD Serono the Healthcare business of Merck KGaA, Zheng Feng, Director and Head, Clinical Genomics, Clinical Biomarker Technologies, EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, Lauri Diehl, Executive Director, Research Pathology, Gilead Sciences, Cecilia Schott, Vice President and Head, Precision Diagnostics, Oncology Translational Medicine R and D, GSK, Mike Washburn, Executive Director and Head, Integrative Sciences, Oncology Translational Medicine, GSK, Angela Silvestro, Director, Companion Diagnostics, GSK, Andrea Stevens, Senior Director, Precision Medicine Access, Johnson and Johnson Innovative Medicine, Viraj Tyagi, Global Alliance Leader, Precision Medicine and Diagnostics, Johnson and Johnson Innovative Medicine, Neha Kumar, Global Commercial Lead, Precision Medicine Strategy, Johnson and Johnson Innovative Medicine, Fernando Cruz-Guilloty, Director, Oncology Precision Medicine and Diagnostics, Johnson and Johnson Innovative Medicine, Carol Peña, Associate Vice President, Companion Diagnostic Development, Merck, Sid Mathur, Executive Director, Regulatory Diagnostics and Digital Health (RDDH), Merck, Karim Azer, Global Head, Data and AI, Clinical Development, Novartis, Nancy Krunic, Ph.D, Vice President and Precision Medicine Head, Diagnostic Sciences and Partnerships, Novartis, Wendy Valenius, Senior Manager, Global Regulatory Strategy, Companion Diagnostics Oncology, Pfizer, Benjamin Withey, Director, Commercial Diagnostics and Companion Diagnostics Lead, Pfizer, Lindsay Darling, Director, Clinical Laboratory and Diagnostic Delivery, Regeneron, Emanuele De Rinaldis, Vice President and Global Head, Target, Diseases and Systems Biology, Sanofi, Alina Ainbinder, Scientific Associate Director, Takeda, Rowland Illing, Chief Medical Officer and Director, Healthcare and Life Sciences, Amazon Web Services (AWS), David Henderson, Customer Engineer III AI/ML, Life Sciences North, Google Cloud, Alexander Mehmet, Ersoy Director, Industry Advisory, Healthcare and Life Sciences, Microsoft, Lauren Leiman, Executive Director, BLOODPAC, Caroline Koffke, Director, Educational and Healthcare Provider Programs, Living Beyond Breast Cancer, Lee Cooper, Associate Professor, Northwestern University, Haley Director, Board of Directors, Policy, Rare New England, Tasia Rechisky, Board of Directory, Secretary, Policy Co-Lead, Rare Disease Patient and Advocate, Rare New England, Jill Weimer, Senior Director, Therapeutic Development, Sanford Research, Jim Palma, Chief Executive Officer, TargetCancer Foundation, Marshall Thompson, Chief Technology Officer, The Rare Cancer Research Foundation, Matthew G.Hanna, Vice Chair, Pathology Informatics, University of Pittsburgh Medical Center, Chloe Delepine, Director, Clinical Biomarkers, Agenus, Shruti Gopal Vij, Director, Innovation and AI Strategy, Alexion Pharmaceuticals, Michael Stocum, President and Chief Executive Officer, Bantam Pharmaceutical, Priya S. Chockalingam, Vice President and Head, Clinical Bioanalytics and Translational Sciences, Beam Therapeutics, Francesca Barone, Chief Scientific Officer, Candel Therapeutics, Kris Sachsenmeier, Vice President, Translational Sciences, Compass Therapeutics, Jarema (Jarko) Kochan, Senior Director, Clinical Biomarkers and Clinical Development, Eikon Therapeutics, Katie Newhall, Executive Director, Translational Biomarkers and Diagnostics, Immunome, John Goldberg, Acting Chief Development Officer, Incendia Therapeutics, Jeff Jackson, Group Vice President, Translational Medicine, Incyte, Robin Edwards, Vice President, Translational Medicine, MacroGenics, Brian Tunquist, Senior Director, Translational Medicine, OnKure Therapeutics, Marla Weetall, Senior Vice President, Pharmacology and Biomarkers, PTC Therapeutics, Marsha Crochiere, Vice President, Translational Medicine and Research, Pyxis Oncology, David Chen, Senior Director, Precision Medicine and Companion Diagnostics, Revolution Medicines, Scott Yohe, Senior Vice President, Managed Markets and Access Strategy, Rigel Pharmaceutical, Marie Du, Executive Director, Biomarker and Translational Operations, Vanqua Bio, Erin Grath, Associate Vice President, Regulatory Affairs, Agilent Technologies, Stewart McWilliams, Global Vice President, Quality and Regulatory Affairs, Almac Diagnostic Services, Matt Pink, Vice President, Business Development, Biodesix, Carla Kantara, Vice President and Head, Enterprise Partnering, Caris Life Sciences, Gulfem Guler, Vice President, Translational Research, ClearNote Health, Heather Cohen, Vice President, Precision Medicine and Biomarkers, Create Medicines, Matthew Maland, Director, Regulatory Affairs, EntroGen, Eric Fung, Senior Vice President, Clinical Development, Population Health and Biostatistics, GRAIL, Hosein Kouros-Mehr, Senior Vice President, R and D, Myriad Genetics, Hedi Ben Brahim, Chief Executive Officer, One Biosciences